Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2011-06-21
2011-06-21
Fronda, Christian L (Department: 1652)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C424S178100, C435S252300, C435S320100, C530S350000, C536S023100
Reexamination Certificate
active
07964375
ABSTRACT:
A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.
REFERENCES:
patent: 2005/0202538 (2005-09-01), Gilles et al.
Chica et al. Curr Opin Biotechnol. Aug. 2005;16(4):378-84.
Sen et al. Appl Biochem Biotechnol. Dec. 2007;143(3):212-23.
Terminal Disclaimer filed Feb. 21, 2011 for U.S. Appl. No. 12/162,320, Wang et al., filed Jan. 25, 2007, which is a 371 of International Application No. PCT/CA2007/000107, which is a CIP of U.S. Appl. No. 11/340,661, Wang et al., filed Jan. 27, 2007 (now US Patent No. 7625564).
Office Action mailed Feb. 25, 2011 for U.S. Appl. No. 12/180,455, Wang et al., filed Jul. 25, 2008.
Office Action (Restriction Requirement) mailed Mar. 7, 2011 for U.S. Appl. No. 12/755,743, Wang et al., filed Sep. 8, 2009, which is a divisional of U.S. Appl. No. 11/340,661, Wang et al., filed Jan. 27, 2007 (now US Patent No. 7625564).
Liu Longbin
Wang Haitao
Xu Jing
Yong Du
Zhang Rui
Fronda Christian L
Novagen Holding Corporation
Oyen Wiggs Green & Mutala LLP
LandOfFree
Polynucleotides encoding human EPO-FC fusion proteins with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotides encoding human EPO-FC fusion proteins with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotides encoding human EPO-FC fusion proteins with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2708266